IN THE MATTER OF

\* BEFORE THE

MALIKAH SCRIBER

\* STATE BOARD

**PHARM TECH** 

OF

Registration No.: T15361

PHARMACY

Respondent

Case No. PT-17-001

## ORDER FOR SUMMARY SUSPENSION

Pursuant to Md. State Gov't. (SG) Code Ann. §10-226 (c) (2) (2014 Repl. Vol. II), the State Board of Pharmacy (the "Board") hereby suspends the registration to practice as a Pharmacy Technician (Pharm Tech) in Maryland issued to **MALIKAH SCRIBER**, (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md. Health Occ. Code Ann. §§ 12-101 *et seq*. (2014 Repl. Vol. II). This Order is based on the following investigative findings, which the Board has reason to believe are true:

# **INVESTIGATIVE FINDINGS**<sup>1</sup>

- At all times relevant hereto, the Respondent was registered to practice as a Pharmacy Technician in Maryland. The Respondent was first registered on October 22, 2014. The Respondent's registration expires on February 28, 2018.
- 2. At all times relevant hereto, the Respondent was employed as a Pharmacy Technician at a pharmacy within a chain pharmacy in Baltimore, Maryland, hereinafter "Pharmacy A."

<sup>&</sup>lt;sup>1</sup>The allegations set forth in this Order are intended to provide the Respondent with notice of the Board's action. They are not intended as, and do not necessarily represent, a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in connection with this Order.

- 3. On July 1, 2016, the Board received a Drug Enforcement Administration (DEA) "Report of Theft or Loss of Controlled Substances" from Pharmacy A indicating that the Respondent committed employee pilferage of Alprazolam<sup>2</sup>, 2 mg, 1343 tablets.
- 4. On July 7, 2016, the Board received Pharmacy A's investigative file which disclosed the following information:
  - A. Pharmacy A's Investigative Specialist determined that Alprazolam was being negatively keyed out in Pharmacy A's ordering system, even though there were no drugs being dispensed to support the inventory being sold;
  - B. As a result, covert cameras were installed and, after viewing same, the Respondent was recorded concealing the Alprazolam, 2mg tablets from the bottle after keying in a negative adjustment of -63 tablets;
  - C. On June 28, 2016, Pharmacy A's Specialist interviewed the Respondent in the store manager's office where the Respondent admitted during a video interview and via a written statement to a theft scheme involving the Alprazolam tablets;
  - D. The Respondent admitted that she had stolen 1343 tablets at a rate of approximately 200 tablets a week since April 2016;
  - E. Based upon the above, the Respondent was terminated from employment with Pharmacy A;

<sup>&</sup>lt;sup>2</sup> Alprazolam, brand name Xanax, is a prescription drug used to treat anxiety disorders, such as generalized anxiety disorder (GAD), anxiety associated with depression, and panic disorder. Other uses include treatment of depression and premenstrual syndrome (PMS). It is in a class of drugs called benzodiazepines.

F. The Respondent claimed that she was stealing the tablets to "support" her daughter.

#### CONCLUSIONS OF LAW

Based on the foregoing, the Board finds that the public health, safety or welfare imperatively requires emergency action, pursuant to Md. St. Gov't. Code Ann. §10-226 (c) (2) (2014 Repl. Vol. II).

#### **ORDER**

ORDERED that, upon the Board's receipt of a written request from the Respondent, a Show Cause Hearing shall be scheduled within a reasonable time of said request, at which the Respondent will be given an opportunity to be heard as to whether the Summary Suspension should be continued, regarding the Respondent's fitness to practice as a Pharmacy Technician and the danger to the public; and be it further

ORDERED, that the Respondent shall immediately turn over to the Board her wall certificate and wallet-sized registration to practice as a Pharmacy Technician issued by the Board; and be it further

ORDERED, that this document constitutes a final Order of the Board and is,

therefore, a public document for purposes of public disclosure, as required by Md. Code Ann. Gen. Prov. §§ 4-101, et seq.

Deena Speights-Napata, Executive Director

Board of Pharmacy

### **NOTICE OF HEARING**

A Show Cause hearing to determine whether the Summary Suspension shall be continued will be held before the Board at 4201 Patterson Avenue, Baltimore, 21215 following a written request by the Respondent for same.